Zumutor Biologics Secures $7.3 Million to Propel Novel Cancer Immunotherapy Trials Under FDA Oversight
What is the news?
In a significant milestone for the international life sciences corridor, cross-border biotechnology innovator Zumutor Biologics has successfully closed a $7.3 million Pre-Series B funding round. Spearheaded by existing investors Accel and Bharat Innovation Fund, the round also attracted prominent strategic participation from Premji Invest, seasoned investor Ashish Kacholia, and the Raj Dandu Family Office. This fresh injection of capital solidifies the company’s financial runway as it enters crucial validation stages for its cutting-edge oncology assets.
Why is it interesting?
Founded and led by visionary entrepreneur Kavitha Iyer Rodrigues, Zumutor Biologics is carving out a premier reputation within the global therapeutic landscape. Operating dual research facilities across the strategic biotech hubs of Bengaluru, India, and Cambridge, Massachusetts, the firm embodies the core spirit of the founders community building from India for the world. The company focuses on developing next-generation immuno-oncology therapies that effectively harness the human body’s innate immune system, specifically utilizing natural killer (NK) cells to target and dismantle hard-to-treat solid tumors.
The primary allocation of the newly raised funding is heavily earmarked for clinical progression. Specifically, the capital will finalize the ongoing US FDA Phase 1 clinical trials of its first-in-class lead drug candidate, ZM008. Furthermore, it will facilitate the rollout of Phase 1B expansion cohorts and layout the infrastructure required to launch multi-country Phase 2 studies. By seamlessly intertwining Indian intellectual capital with global regulatory frameworks, Zumutor continues to validate India’s emergence as a premium knowledge and high-tech innovation center.
Read more: Zumutor Biologics raises $7.3 Mn in Pre-Series B round